Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus apatinib in advanced hepatocellular carcinoma
CTR20180270Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, latanoprost in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Mar 2018; status: completed.
02
Drugs
camrelizumablatanoprost
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20180270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180270.